Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 67

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 67
---
 study in SCD by the end of the fourth quarter. |

| 3) | Advance and diversify pipeline: relative weighting 15% |

| • |     | Achieve first-patient-in for the phase 2b study of AG-946 in LR MDS by the end of the third quarter; |

| • |     | Achieve last-patient-in for the core single ascending dose study cohorts for the phase 1 study of AG-181 by the end of the fourth quarter; and |

| • |     | Advance one new program to the next defined stage. |

| 4) | Maintain financial strength and develop our strategy, organization and culture to ensure execution of the company’s long-term vision: relative weighting 15% |

| • |     | Spend within forecast; |

| • |     | Ensure that we maintain a cash runway into 2027 by the end of the year; |

| • |     | Engage a distributed workforce through high connectivity and ensure retention of key capabilities; and |

| • |     | Drive culture of inclusion and belonging across employee population. |

Certain of these corporate goals include highly sensitive and competitive data, including preclinical, clinical, regulatory, strategic and financial targets. We do not disclose the specific portions of these goals because we believe that such disclosure would result in competitive harm to us. We purposely set these goals at challenging levels. Revealing certain elements of these goals could potentially reveal insights about our preclinical, clinical, regulatory, financial and strategic plans or objectives that our competitors or potential collaborators could use against us. In January 2025, our chief executive officer recommended to our compensation & people committee that our company’s performance against 2024 goals be assessed based on the company’s achievements against these goals during the year, which achievements are discussed above under “Compensation Discussion and Analysis— Executive Summary”. Based on the company’s achievements against our 2024 goals, the overall company performance score for 2024 was determined to be 125% by our board of directors upon the recommendation of 49

the compensation & people committee. Below is our relative weighted performance against our 2024 goals, as determined by our board of directors.

| 2024 Corporate Goals                                                                                                                 |     | Weighting |     |   |     | Assessment     
 of Achievement |     |    |     | Weighted    
 Performance |     |   |
| Set foundation for future of hemolytic anemia franchise through launch readiness and global planning                                 |     |           |